Safety and efficacy of botulinum toxin type A following long-term use

M. Naumann, A. Albanese, F. Heinen, G. Molenaers, M. Relja

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

Botulinum toxin serotype A (BoNT-A) has long heritage of use leading to confidence in its safety and efficacy. The application of BoNT-A does not lead to persistent histological changes in the nerve terminal or the target muscle. Clinical trials defined the safety and tolerability profile of BoNT-A across common therapeutic indications and showed an incidence of adverse events of approximately 25% in the BoNT-A-treated group compared with 15% in the control group. Focal weakness was the only adverse event to occur more often following BoNT-A treatment. Long-term BoNT-A administration has been assessed in various treatment settings, with the level and duration of BoNT-A efficacy response being maintained over repeated rounds of injection with no major safety concerns. The treatment of children with cerebral palsy often require long-term, repeated, multimuscle BoNT-A injections that lead to the administration of comparably higher toxin doses. Despite the high total body doses used, their distribution over multiple muscles and injection sites means that systemic side effects are rare. Recent formulation changes have reduced the incidence of antibody development following treatment with BOTOX®. These findings show long-term BoNT-A treatment to be both safe and efficacious for a wide variety of indications.

Original languageEnglish
Pages (from-to)35-40
Number of pages6
JournalEuropean Journal of Neurology
Volume13
Issue numberSUPPL. 4
DOIs
Publication statusPublished - Dec 2006

Fingerprint

Type A Botulinum Toxins
Safety
Injections
Therapeutics
Serogroup
Muscles
Incidence
Cerebral Palsy
Clinical Trials
Control Groups
Antibodies

Keywords

  • Botulinum toxin serotype A
  • Long-term treatment
  • Neutralizing antibodies

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Safety and efficacy of botulinum toxin type A following long-term use. / Naumann, M.; Albanese, A.; Heinen, F.; Molenaers, G.; Relja, M.

In: European Journal of Neurology, Vol. 13, No. SUPPL. 4, 12.2006, p. 35-40.

Research output: Contribution to journalArticle

Naumann, M. ; Albanese, A. ; Heinen, F. ; Molenaers, G. ; Relja, M. / Safety and efficacy of botulinum toxin type A following long-term use. In: European Journal of Neurology. 2006 ; Vol. 13, No. SUPPL. 4. pp. 35-40.
@article{f3f1841f0c3949b1ba4c83af80757ecf,
title = "Safety and efficacy of botulinum toxin type A following long-term use",
abstract = "Botulinum toxin serotype A (BoNT-A) has long heritage of use leading to confidence in its safety and efficacy. The application of BoNT-A does not lead to persistent histological changes in the nerve terminal or the target muscle. Clinical trials defined the safety and tolerability profile of BoNT-A across common therapeutic indications and showed an incidence of adverse events of approximately 25{\%} in the BoNT-A-treated group compared with 15{\%} in the control group. Focal weakness was the only adverse event to occur more often following BoNT-A treatment. Long-term BoNT-A administration has been assessed in various treatment settings, with the level and duration of BoNT-A efficacy response being maintained over repeated rounds of injection with no major safety concerns. The treatment of children with cerebral palsy often require long-term, repeated, multimuscle BoNT-A injections that lead to the administration of comparably higher toxin doses. Despite the high total body doses used, their distribution over multiple muscles and injection sites means that systemic side effects are rare. Recent formulation changes have reduced the incidence of antibody development following treatment with BOTOX{\circledR}. These findings show long-term BoNT-A treatment to be both safe and efficacious for a wide variety of indications.",
keywords = "Botulinum toxin serotype A, Long-term treatment, Neutralizing antibodies",
author = "M. Naumann and A. Albanese and F. Heinen and G. Molenaers and M. Relja",
year = "2006",
month = "12",
doi = "10.1111/j.1468-1331.2006.01652.x",
language = "English",
volume = "13",
pages = "35--40",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Safety and efficacy of botulinum toxin type A following long-term use

AU - Naumann, M.

AU - Albanese, A.

AU - Heinen, F.

AU - Molenaers, G.

AU - Relja, M.

PY - 2006/12

Y1 - 2006/12

N2 - Botulinum toxin serotype A (BoNT-A) has long heritage of use leading to confidence in its safety and efficacy. The application of BoNT-A does not lead to persistent histological changes in the nerve terminal or the target muscle. Clinical trials defined the safety and tolerability profile of BoNT-A across common therapeutic indications and showed an incidence of adverse events of approximately 25% in the BoNT-A-treated group compared with 15% in the control group. Focal weakness was the only adverse event to occur more often following BoNT-A treatment. Long-term BoNT-A administration has been assessed in various treatment settings, with the level and duration of BoNT-A efficacy response being maintained over repeated rounds of injection with no major safety concerns. The treatment of children with cerebral palsy often require long-term, repeated, multimuscle BoNT-A injections that lead to the administration of comparably higher toxin doses. Despite the high total body doses used, their distribution over multiple muscles and injection sites means that systemic side effects are rare. Recent formulation changes have reduced the incidence of antibody development following treatment with BOTOX®. These findings show long-term BoNT-A treatment to be both safe and efficacious for a wide variety of indications.

AB - Botulinum toxin serotype A (BoNT-A) has long heritage of use leading to confidence in its safety and efficacy. The application of BoNT-A does not lead to persistent histological changes in the nerve terminal or the target muscle. Clinical trials defined the safety and tolerability profile of BoNT-A across common therapeutic indications and showed an incidence of adverse events of approximately 25% in the BoNT-A-treated group compared with 15% in the control group. Focal weakness was the only adverse event to occur more often following BoNT-A treatment. Long-term BoNT-A administration has been assessed in various treatment settings, with the level and duration of BoNT-A efficacy response being maintained over repeated rounds of injection with no major safety concerns. The treatment of children with cerebral palsy often require long-term, repeated, multimuscle BoNT-A injections that lead to the administration of comparably higher toxin doses. Despite the high total body doses used, their distribution over multiple muscles and injection sites means that systemic side effects are rare. Recent formulation changes have reduced the incidence of antibody development following treatment with BOTOX®. These findings show long-term BoNT-A treatment to be both safe and efficacious for a wide variety of indications.

KW - Botulinum toxin serotype A

KW - Long-term treatment

KW - Neutralizing antibodies

UR - http://www.scopus.com/inward/record.url?scp=33751021134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751021134&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1331.2006.01652.x

DO - 10.1111/j.1468-1331.2006.01652.x

M3 - Article

C2 - 17112348

AN - SCOPUS:33751021134

VL - 13

SP - 35

EP - 40

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - SUPPL. 4

ER -